Parabilis Medicines Inc
PBLS
79 hedge funds and large institutions have $2.71B invested in Parabilis Medicines Inc in 2026 Q2 according to their latest regulatory filings, with 79 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
84.46% more ownership
Funds ownership: 0% → 84.46% (+84%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$799M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$284M |
| 3 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$177M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
+$145M |
| 5 |
AI
Alphabet Inc
Mountain View,
California
|
+$136M |
Top Sellers
PBLS Hedge Fund Activity: Q2 2026 in Review
79 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Parabilis Medicines Inc (PBLS) for Q2 2026, worth a combined $2.71B.
Buyers outnumbered sellers: 79 funds opened new PBLS positions and 0 closed out — a net gain of 79 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $799M.
- 79 institutional investors held Parabilis Medicines Inc (PBLS) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $2.71B of Parabilis Medicines Inc stock for Q2 2026.
- 79 funds opened new Parabilis Medicines Inc positions in Q2 2026 and 0 closed out, a net change of +79 holders.
- The largest Parabilis Medicines Inc buyer in Q2 2026 was RA Capital Management, an estimated $799M added.
Based on aggregated 13F filings for Q2 2026.